drugset

drugset / Trial / NCT01904721

A Safety and Efficacy Study of Bimatoprost in Men With Androgenic Alopecia (AGA)

NCT01904721 ↗

Phase 2 Completed 244 enrolled Allergan

RandomizedParallel-groupTriple-blindTreatment

Summary

This is a safety and efficacy study of bimatoprost in male subjects with androgenic alopecia (AGA).

Timeline

Start: 2013-08
Primary completion: 2014-09
Completion: 2015-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bimatoprost	Other / unclassified	—	Topical

Indications